IPH-62

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameIPH-62
Drug Alias NameIPH62/NKp46 NKCEIPH-62
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionCD276 antigen modulatorsNatural cytotoxicity triggering receptor 1 inhibitorsLow affinity immunoglobulin gamma Fc region receptor III-A modulators
TargetsCD276 antigenNatural cytotoxicity triggering receptor 1Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInnate Pharma
China Registration ClassN/A

Develop Information

Active CompaniesSanofiInnate Pharma
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A